SCHEMBL16587740

SCHEMBL16587740

CCC1CN(S(C)(=O)=O)CC1C(C)C

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
CYP2D6 P10635 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16587739 0.84 TSHR (0.38) TSHRCYP2D6SMN1; SMN2
SCHEMBL16472340 0.84 TSHR (0.38) TSHRCYP2D6SMN1; SMN2
SCHEMBL16478643 0.75 TP53 (0.32)
SCHEMBL16472260 0.75 TSHR (0.33) TSHRCYP2D6SMN1; SMN2
SCHEMBL16472417 0.75 TP53 (0.32)
SCHEMBL24634255 0.75 TSHR (0.33) TSHRCYP2D6SMN1; SMN2
SCHEMBL16478635 0.73 TP53 (0.31)
SCHEMBL16472323 0.70
SCHEMBL19447726 0.70
SCHEMBL16478732 0.69 TP53 (0.42) TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987268-B2 Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-24 US disclosed